Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382824 · ClinicalTrials.gov registry record · NA
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
A NA study, sponsored by Lahey Clinic.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT00382824: Completed NA study, sponsored by Lahey Clinic.
NCT00382824 is a NA study that has completed, run by Lahey Clinic. The registered enrollment target is 61 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00382824, a NA study, has completed, sponsored by Lahey Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists. Coenzyme Q10 in high doses has been shown to be a beneficial therapy in PD and might possibly be a beneficial therapy for PSP. This study will compare the efficacy, safety and tolerability of Coenzyme Q10 versus placebo in patients with atypical parkinsonian syndrome, progressive supranuclear palsy (PSP).
Primary Outcome
Unified Parkinson's Disease Rating Scale \[UPDRS\]: Higher scores indicate a higher degree of impairment The total score is calculated by summing the subscores. Total scores range from 0 (normal) to 166 (severely impaired) Part I \[Mentation, Behavior, \& Mood\] Scale: 0-16 Part II \[Activities of Daily Living, Both "ON" \& "OFF"\] Scale:0-52 Part III \[Motor Examination\] Scale: 0-56 Part IV \[Complications of Therapy\] Scale: 0-34 Part V \[Modified Hoehn \& Yahr Staging\] Scale: 0-8 Part VI \[
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Coenzyme Q10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2006-09 |
| Est. Completion | 2015-01 |
| Phase | NA |
What the finished NCT00382824 record still lists
NCT00382824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00382824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00382824 about?
NCT00382824 is a clinical study titled "Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)". The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists. Coenzyme Q10 in high doses has been shown to be a beneficial therapy in PD and might possibly be a beneficial therapy for PSP. This study will co...
What is the current status of trial NCT00382824?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2006-09. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00382824?
The interventions under investigation include: Placebo (OTHER), Coenzyme Q10 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00382824?
This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00382824's enrollment target sits among peer trials
61 1164th of 2000 higher than 837 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia